Last reviewed · How we verify
PHIT
PHIT, marketed by the Andalusian Network for Design and Translation of Advanced Therapies, holds an unspecified market position with its primary indication and revenue details undisclosed. The key composition patent for PHIT is set to expire in 2028, which may present a significant competitive advantage until then. However, the primary risk lies in the unknown mechanism of action, which could limit further development and regulatory support.
At a glance
| Generic name | PHIT |
|---|---|
| Sponsor | Andalusian Network for Design and Translation of Advanced Therapies |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Function in Older Veterans With Hospital-Associated Deconditioning (NA)
- Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery (PHASE2)
- A Behavioral Science-Enhanced PHysician-led Remote Group Exercise InTervention for Women With Coronary Artery Disease (NA)
- Proactive Health Intervention for Tobacco Users (Get PHIT) (PHASE2,PHASE3)
- Effect of a High-Protein Diet and/or High-Intensity Training on Metabolic Syndrome (NA)
- Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHIT CI brief — competitive landscape report
- PHIT updates RSS · CI watch RSS
- Andalusian Network for Design and Translation of Advanced Therapies portfolio CI